Acurx Pharmaceuticals (ACXP) vs NeuroSense Therapeutics (NRSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acurx Pharmaceuticals is the larger company by market cap ($6.9 million vs $6.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACXP | NRSN |
|---|---|---|
| Share price | $1.25 | $3.58 |
| Market cap | $6.95M | $6.79M |
| 1-day change | -3.85% | -6.28% |
| EPS (TTM) | $-2.67 | $-47.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.98 | $26.64 |
| 52-week low | $1.23 | $3.56 |
| Distance from 52-week high | -84.34% | -86.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1260.00% | +2618.72% |
| Average volume | 125.08K | 21.29K |
| Shares outstanding | 5.56M | 1.90M |
| Employees | 4 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acurx Pharmaceuticals
ACXP stock →Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Healthcare · Biotechnology · 4 employees
About NeuroSense Therapeutics
NRSN stock →NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Healthcare · Biotechnology · 17 employees
ACXP vs NRSN FAQ
Which is bigger, Acurx Pharmaceuticals or NeuroSense Therapeutics?
Acurx Pharmaceuticals (ACXP) is larger, with a market capitalization of $6.95M compared with $6.79M for NeuroSense Therapeutics (NRSN).
Are Acurx Pharmaceuticals and NeuroSense Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.